Core Viewpoint - Dongyang Sunshine Group's subsidiary, Dongyang Sunshine Pharmaceutical, has entered into a strategic partnership with Crystal Tech Holdings to establish a joint venture aimed at creating an industry-leading AI drug development engine, with an investment of several hundred million yuan [1] Group 1: Partnership Details - The joint venture will focus on leveraging Dongyang Sunshine Pharmaceutical's extensive real-world data assets, which include over 150 approved drugs and more than 100 drugs in development, alongside Crystal Tech's unique advantages in quantum physics, AI, and robotics [1] - The collaboration aims to accelerate the discovery and clinical translation of candidate drugs in the field of autoimmune diseases by combining Dongyang Sunshine's full-chain R&D experience with Crystal Tech's AI drug development technology [1] Group 2: Technological Integration - The partnership will establish an AI supercomputing platform based on a "computing power + data + ecosystem" model, which will be open to collaboration with academia and industry [1] - The goal is to transform data assets and AI products into a "Model as a Service" (MaaS) business model, enhancing the commercial viability of their joint efforts [1]